Brian Orelli, PhD

TMFBiologyFool

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Articles by Brian Orelli, PhD — Page 8

Jan 4, 2021 by Brian Orelli, PhD

3 Takeaways for Investors in mRNA Vaccine Stocks

Vaccine side effects, mutations in the virus, and company pipelines are some of the things investors should be watching.

Jan 4, 2021 by Brian Orelli, PhD

Here's Why Drugmakers Face a Dilemma Now That 2 Vaccines Are Rolling Out

The authorizations are going to make it harder for late-comers to run clinical trials.

Jan 3, 2021 by Brian Orelli, PhD

Should Investors Be Worried About Pfizer and BioNTech's Coronavirus Vaccine Rollout?

The slow rollout is concerning, but we also need more information to know whether allergic reactions are a big deal.

Jan 3, 2021 by Brian Orelli, PhD

Here's What Investors Need to Know About Sanofi and GlaxoSmithKline's COVID Vaccine Setback

Hopefully, the backup plan works.

Dec 21, 2020 by Brian Orelli, PhD

This Biotech Skyrocketed 84% in 2 Days, But Is It Warranted?

Short squeezes don't typically live up to their expectations.

Dec 21, 2020 by Brian Orelli, PhD

Is AstraZeneca Paying Too Much for Alexion?

Dig a little deeper into the valuation.

Dec 20, 2020 by Brian Orelli, PhD

3 Huge Takeaways for Coronavirus Vaccine Investors

Don't miss these short-term and long-term issues.

Dec 19, 2020 by Brian Orelli, PhD

Here's What Investors Should Know About AstraZeneca's COVID Vaccine Data

The mysterious case of the half-dose.

Dec 19, 2020 by Brian Orelli, PhD

Here's What Investors Need to Know About Pfizer and BioNTech's Vaccine Launch

Manufacturing is a black box for investors.

Dec 18, 2020 by Brian Orelli, PhD

Moderna Gains FDA Authorization for Its Coronavirus Vaccine

A second vaccine is available in the U.S.

Dec 17, 2020 by Brian Orelli, PhD

FDA Advisers Vote Unanimously Recommending Authorization of Moderna's Coronavirus Vaccine

The FDA could issue an emergency use authorization on Friday.

Dec 16, 2020 by Brian Orelli, PhD

Coronavirus Vaccine Stocks: What Investors Should Know About The FDA and Rollouts

Generating clinical trial data was hard, but the work isn't over for the vaccine makers.

Dec 13, 2020 by Brian Orelli, PhD

Should Investors Buy Inovio for Its Coronavirus Vaccine?

The biotech is trailing the leaders.

Dec 13, 2020 by Brian Orelli, PhD

Why Did This Big Investor Sell Its Moderna Stock?

Not all sales are done because the investor thinks a stock is overvalued.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services